HK1252350A1 - Mrka多肽、抗体及其用途 - Google Patents

Mrka多肽、抗体及其用途 Download PDF

Info

Publication number
HK1252350A1
HK1252350A1 HK18111635.8A HK18111635A HK1252350A1 HK 1252350 A1 HK1252350 A1 HK 1252350A1 HK 18111635 A HK18111635 A HK 18111635A HK 1252350 A1 HK1252350 A1 HK 1252350A1
Authority
HK
Hong Kong
Prior art keywords
mrka
klebsiella
antibodies
fragments
subject
Prior art date
Application number
HK18111635.8A
Other languages
English (en)
Chinese (zh)
Inventor
Qun Wang
Saravanan RAJAN
Chew-Shun Chang
Jenny HEIDBRINK THOMPSON
Hung-Yu Lin
Charles Kendall Stover
Meghan PENNINI
William Dall'acqua
Partha S. Chowdhury
Xiaodong Xiao
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of HK1252350A1 publication Critical patent/HK1252350A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK18111635.8A 2015-08-24 2016-08-23 Mrka多肽、抗体及其用途 HK1252350A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562208975P 2015-08-24
US201562238828P 2015-10-08 2015-10-08
US201562238828P 2015-10-08

Publications (1)

Publication Number Publication Date
HK1252350A1 true HK1252350A1 (zh) 2019-05-24

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111635.8A HK1252350A1 (zh) 2015-08-24 2016-08-23 Mrka多肽、抗体及其用途

Country Status (16)

Country Link
US (2) US20170073397A1 (enExample)
EP (1) EP3341004A4 (enExample)
JP (1) JP2018527924A (enExample)
KR (1) KR20180042300A (enExample)
CN (1) CN107921086A (enExample)
AU (1) AU2016313653A1 (enExample)
BR (1) BR112018003252A2 (enExample)
CA (1) CA2995387A1 (enExample)
CL (1) CL2018000357A1 (enExample)
CO (1) CO2018001985A2 (enExample)
HK (1) HK1252350A1 (enExample)
IL (1) IL257434A (enExample)
MX (1) MX2018001964A (enExample)
RU (1) RU2018107056A (enExample)
TW (1) TW201718626A (enExample)
WO (1) WO2017035154A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2012058334A1 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Morphology & protein specific reagents as diagnostics for neurodegenerative diseases
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas

Also Published As

Publication number Publication date
CL2018000357A1 (es) 2018-07-20
JP2018527924A (ja) 2018-09-27
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
AU2016313653A1 (en) 2018-04-12
CO2018001985A2 (es) 2018-11-22
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
CN107921086A (zh) 2018-04-17
MX2018001964A (es) 2018-06-19
US20190062411A1 (en) 2019-02-28
EP3341004A1 (en) 2018-07-04
EP3341004A4 (en) 2019-05-15
WO2017035154A1 (en) 2017-03-02
BR112018003252A2 (pt) 2018-09-25
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
HK1252350A1 (zh) Mrka多肽、抗体及其用途
HK1252666A1 (zh) 针对cd40的抗体
WO2018005682A3 (en) Pd-l1-specific antibodies and methods of using the same
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2014004549A3 (en) Anti-mesothelin binding proteins
TN2017000025A1 (en) Anti-lag3 antibodies and antigen-binding fragments.
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2018027124A8 (en) ANTI-O2 ANTIBODIES AND USES THEREOF
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
WO2018069871A3 (en) Anti-kras binding proteins
EA201990895A1 (ru) Антитела к о1 и варианты их применения
WO2015157322A3 (en) Anti-nme antibody
WO2017019957A3 (en) Binding proteins and methods of use thereof
WO2016020880A3 (en) Angiopoietin-like 4 antibodies and methods of use
PH12019501050A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use
EP3269735A4 (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof